triazoles has been researched along with trametinib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buijsman, RC; de Man, J; de Roos, JA; de Vetter, JR; Prinsen, MB; Spijkers-Hagelstein, JA; Uitdehaag, JC; van Doornmalen, AM; Zaman, GJ | 1 |
| Arango, D; Chueh, AC; Dawson, MA; Dhillon, AS; Diez-Dacal, B; Filippakopoulos, P; Gahman, TC; Jayachandran, A; Mariadason, JM; Nightingale, R; Phesse, T; Shiau, AK; Sieber, OM; Tögel, L; Tran, H; Wu, R | 1 |
| Angus, SP; Beltran, AS; Bevill, SM; Carey, LA; Chen, X; Darr, DB; Duncan, JS; Earp, HS; Gallagher, K; Golitz, BT; Goulet, DR; Graves, LM; He, X; Johnson, GL; Olivares-Quintero, JF; Parker, JS; Perou, CM; Rashid, NU; Santos, C; Sciaky, N; Singh, D; Stuhlmiller, TJ; Velarde, SH; Whittle, MC; Zawistowski, JS | 1 |
| Assiotis, I; Box, G; Chauhan, R; Cunningham, D; De Haven Brandon, A; Eason, K; Isacke, CM; Jenkins, L; Khan, K; Kirkin, V; Mancusi, C; Manodoro, F; Matthews, N; Robinson, P; Rust, AG; Sadanandam, A; Self, A; Starling, N; Valenti, M; Valeri, N; Vlachogiannis, G; Wagner, S; Whittaker, SR | 1 |
| Adderley, T; Christopher, G; Irwin, MS; Kano, Y; Kee, L; Ladumor, Y; Ohh, M; Robinson, CM; Valencia-Sama, I | 1 |
1 trial(s) available for triazoles and trametinib
| Article | Year |
|---|---|
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Discoidin Domain Receptor 1; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Epigenesis, Genetic; Female; Heterocyclic Compounds, 4 or More Rings; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice, Inbred BALB C; Mice, SCID; Molecular Targeted Therapy; Nuclear Proteins; Positive Transcriptional Elongation Factor B; Pyridones; Pyrimidinones; RNA Interference; Transcription Factors; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
4 other study(ies) available for triazoles and trametinib
| Article | Year |
|---|---|
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aza Compounds; Benzimidazoles; beta Catenin; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Oxazoles; Oximes; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Quinolines; Sulfonamides; Triazoles; Vemurafenib | 2015 |
Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Topics: Animals; Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Synergism; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Proto-Oncogene Proteins c-myc; Pyridones; Pyrimidinones; Triazoles; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.
Topics: Animals; Azepines; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Interferons; Mice; Mutation; Organoids; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Triazoles; Xenograft Model Antitumor Assays | 2019 |
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, ras; Heterografts; Humans; Indoles; Male; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Recurrence, Local; Neuroblastoma; Piperidines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Triazoles; Vemurafenib | 2020 |